TREATMENT OF HYPERTHYROID DISEASE

被引:87
作者
KLEIN, I
BECKER, DV
LEVEY, GS
机构
[1] NEW YORK HOSP, CORNELL MED CTR, NEW YORK, NY USA
[2] MERCK & CO INC, WHITE HOUSE STN, NJ USA
关键词
D O I
10.7326/0003-4819-121-4-199408150-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To evaluate treatments for hyperthyroid disease. Data Sources: Selected studies published during the last 20 years addressing the diagnosis, causes, and treatment of hyperthyroid disease. Study Selection: Studies were chosen based on their usefulness in addressing specific points in the treatment of hyperthyroid disease. Data Extraction: Various treatment principles extracted from the references form the basis for the conclusions and recommendations made here. Results: Hyperthyroid disease is a common endocrine disease. Although Graves disease is the most common cause of thyrotoxicosis, other primary and secondary causes exist. With classic signs and symptoms accompanied by confirmatory laboratory measures of thyroid hyperfunction, the diagnosis can be established firmly. Radioiodine is the preferred method to treat Graves disease; however, recent data concerning treatment with a combination of propylthiouracil and thyroxine require further evaluation to establish its efficacy. Radioiodine is also the preferred treatment for the other forms of hyperthyroid disease; however, patient-specific considerations in both may require patient-tailored therapies. Conclusions: Hyperthyroid disease can be treated definitively for most patients. Palliative therapy with P-adrenergic blockade is useful in some patients. Further studies are needed to determine whether more recently described treatments have improved efficacy and whether therapy directed specifically at the underlying immunologic cause of Graves disease can be used successfully.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 59 条
[1]   CLINICAL AND CHEMICAL ASSESSMENT OF THYROID-FUNCTION DURING THERAPY WITH AMIODARONE [J].
AMICO, JA ;
RICHARDSON, V ;
ALPERT, B ;
KLEIN, I .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (03) :487-490
[2]   DISSECTING THE IMMUNE-RESPONSE TO THE THYROTROPIN RECEPTOR IN AUTOIMMUNE THYROID-DISEASE [J].
BAKER, JR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (01) :16-18
[3]   USE OF CORTICOSTEROIDS TO PREVENT PROGRESSION OF GRAVES OPHTHALMOPATHY AFTER RADIOIODINE THERAPY FOR HYPERTHYROIDISM [J].
BARTALENA, L ;
MARCOCCI, C ;
BOGAZZI, F ;
PANICUCCI, M ;
LEPRI, A ;
PINCHERA, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (20) :1349-1352
[4]  
BECKER D, 1988, DIAGNOSTIC NUCL MED, P778
[5]  
BECKER DV, 1991, PROGRESS IN THYROID RESEARCH, P223
[6]   CHOICE OF THERAPY FOR GRAVES HYPERTHYROIDISM [J].
BECKER, DV .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (07) :464-466
[7]  
BECKER DV, 1982, NUCL MED ANN, P265
[8]   CARDIAC EFFECTS OF LONG-TERM THYROTROPIN-SUPPRESSIVE THERAPY WITH LEVOTHYROXINE [J].
BIONDI, B ;
FAZIO, S ;
CARELLA, C ;
AMATO, G ;
CITTADINI, A ;
LUPOLI, G ;
SACCA, L ;
BELLASTELLA, A ;
LOMBARDI, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (02) :334-338
[9]  
BRADLEY EL, 1980, SURGERY, V87, P623
[10]   THYROID-FUNCTION AND HYPERFUNCTION DURING GESTATION [J].
BURROW, GN .
ENDOCRINE REVIEWS, 1993, 14 (02) :194-202